J Thorac Cardiovasc Surg 2007;133:1118
© 2007 The American Association for Thoracic Surgery
Letter to the Editor
a Department of Cardiothoracic Surgery, Monash University, Department of Surgery, Alfred Hospital and the Baker Heart Research Institute, Melbourne, Australia
b Department of Surgery, The Chinese University of Hong Kong
c Department of Cardiothoracic Surgery, Alfred Hospital Melbourne, Melbourne, Australia
|The first 20% of the full text of this article appears below.|
To the Editor:
We read with interest the article by Thomas Schachner.1 This review was an excellent description of the multiple factors involved in the initiation and progression of neointimal hyperplasia in vein grafts during coronary bypass surgery. Clearly much has been learned in recent years about the type and origin of the cells composing the hyperplastic tissue and other various factors involved in the hyperplastic process. Schachner has proposed multiple pharmacologic strategies to reduce this hyperplastic process.
J. Thorac. Cardiovasc. Surg. 2007 133: 1119.
|HOME||HELP||FEEDBACK||SUBSCRIPTIONS||ARCHIVE||SEARCH||TABLE OF CONTENTS|
|ANN THORAC SURG||ASIAN CARDIOVASC THORAC ANN||EUR J CARDIOTHORAC SURG|
|J THORAC CARDIOVASC SURG||ICVTS||ALL CTSNet JOURNALS|